GZBL(SZ:002424)2014-10-26 16:00Financial Performance - Operating revenue for the reporting period was CNY 321,779,468.86, representing a year-on-year increase of 23.39%[7] - Net profit attributable to shareholders was CNY 42,206,224.11, up 13.82% year-on-year[7] - Basic earnings per share increased by 25.00% to CNY 0.10 for the reporting period[7] - The weighted average return on net assets was 1.93%, an increase of 0.11% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 41,481,874.50, reflecting a 15.11% increase year-on-year[7] - The estimated net profit attributable to shareholders for 2014 is expected to be between 29,600 and 35,000 thousand yuan, representing a growth of 10.00% to 30.00% compared to the previous year[24] - The net profit for 2013 attributable to shareholders was 26,960.45 thousand yuan[24] - The company anticipates stable growth in performance due to normal production operations and a stable sales team[24] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 290,018,085.27, a significant increase of 446.76%[7] - The net cash flow from operating activities for the period was CNY 290,018,085.27, representing a significant year-on-year increase of 446.76% attributed to increased sales and cash inflows[18] - The net cash flow from financing activities was CNY -375,592,537.69, an increase in outflow of CNY 117,810,179.18 compared to the previous year, due to loan repayments[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,266[11] - The largest shareholder, Jiang Wei, holds 52.73% of the shares, with 186,014,400 shares pledged[11] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,350,528,480.77, a decrease of 3.70% compared to the end of the previous year[7] - As of September 30, 2014, accounts receivable amounted to CNY 478,000,185.91, a year-on-year increase of 43.35% due to revenue growth[15] - Other receivables increased by 95.10% to CNY 135,069,465.93, mainly due to marketing deposits and advances to offices[15] - The company reported a 53.83% increase in taxes payable, totaling CNY 51,651,754.81, driven by higher sales and profit[15] - Prepaid accounts increased by 71.76% to CNY 110,046,128.39, reflecting higher advance payments to suppliers[15] - The company’s accounts payable for notes increased to CNY 55,000,000, reflecting increased bank acceptance bill payments to suppliers[15] Management and Expenses - Management expenses reached CNY 102,967,702.26, up 46.31% from the previous year, primarily due to increased investment in new product development and GMP renovation costs[17] - The company reported a 55.17% increase in non-operating income, totaling CNY 3,584,528.98, due to higher government subsidies received[17] Corporate Actions - The company completed the absorption merger of its wholly-owned subsidiary, Tian Taishan Pharmaceutical Co., Ltd., with the legal entity being deregistered[19]